KEGG pathways enriched for interacted genes |
pathway name | pathway description | target genes enrich in pathway | p-value |
|
hsa04012
|
ErbB signaling pathway |
CRK,ERBB2,ERBB3,MAPK8,MAP2K7,EIF4EBP1,CDKN1A, |
6.01E-4 |
hsa05219
|
Bladder cancer |
ERBB2,VEGFA,CDKN1A,E2F3,TP53, |
1.58E-2 |
hsa05212
|
Pancreatic cancer |
ERBB2,MAPK8,VEGFA,RALBP1,E2F3,TP53, |
1.71E-2 |
hsa05200
|
Pathways in cancer |
CRK,ERBB2,MAPK8,COL4A1,VEGFA,RARA,RALBP1,LAMB1,CDKN1A,TCEB2,E2F3,TP53, |
1.76E-2 |
hsa05215
|
Prostate cancer |
ERBB2,CREB5,PDPK1,CDKN1A,E2F3,TP53, |
4.33E-2 |
|
hsa04722
|
Neurotrophin signaling pathway |
CRK,MAPK8,MAP3K1,MAP2K7,TP53,NTRK3, |
1.69E-1 |
hsa05223
|
Non-small cell lung cancer |
ERBB2,PDPK1,E2F3,TP53, |
2.75E-1 |
hsa04510
|
Focal adhesion |
CRK,ERBB2,MAPK8,COL4A1,VEGFA,PDPK1,LAMB1, |
3.46E-1 |
hsa00010
|
Glycolysis / Gluconeogenesis |
ALDH1A3,HK2,TPI1,ENO1, |
3.61E-1 |
hsa04621
|
NOD-like receptor signaling pathway |
CCL5,MAPK8,TNFAIP3,CCL2, |
3.92E-1 |
hsa05220
|
Chronic myeloid leukemia |
CRK,CDKN1A,E2F3,TP53, |
6.27E-1 |
hsa05016
|
Huntington's disease |
DLG4,CREB5,NDUFB6,ATP5G2,SP1,TP53, |
6.72E-1 |
hsa00190
|
Oxidative phosphorylation |
NDUFB6,ND6,ATP5G2,ATP6V1B2,ATP5J2, |
7.30E-1 |
hsa04910
|
Insulin signaling pathway |
CRK,HK2,MAPK8,PDPK1,EIF4EBP1, |
8.14E-1 |
hsa05222
|
Small cell lung cancer |
COL4A1,LAMB1,E2F3,TP53, |
8.21E-1 |
|
|
|
|
|
|
Gene ontology terms enriched for interacted genes |
GO terms | GO terms description | target genes enrich in GO term | p-value |
|
GO:0043066
|
negative regulation of apoptosis |
NUP62,ERBB2,MAPK8,ERBB3,NPM1,CCL2,CDKN1A,TP53,MCL1,G2E3,VEGFA,NME2,TNFAIP3, |
1.43E-4 |
GO:0043069
|
negative regulation of programmed cell death |
NUP62,ERBB2,MAPK8,ERBB3,NPM1,CCL2,CDKN1A,TP53,MCL1,G2E3,VEGFA,NME2,TNFAIP3, |
1.63E-4 |
GO:0060548
|
negative regulation of cell death |
NUP62,ERBB2,MAPK8,ERBB3,NPM1,CCL2,CDKN1A,TP53,MCL1,G2E3,VEGFA,NME2,TNFAIP3, |
1.67E-4 |
GO:0016310
|
phosphorylation |
HK2,WNK3,ERBB2,ERBB3,MAPK8,MAP3K1,IP6K1,YES1,MAP2K7,NDUFB6,ND6,PDPK1,CCL2,NIN,IP6K2,NME2,ATP6V1B2,ATP5G2,SMG1,NTRK3, |
2.02E-4 |
GO:0006793
|
phosphorus metabolic process |
HK2,WNK3,ERBB2,ERBB3,MAPK8,MAP3K1,IP6K1,YES1,MAP2K7,NDUFB6,ND6,PDPK1,CCL2,NIN,IP6K2,NME2,ATP6V1B2,ATP5G2,SMG1,DUSP3,NTRK3, |
8.76E-4 |
|
GO:0006796
|
phosphate metabolic process |
HK2,WNK3,ERBB2,ERBB3,MAPK8,MAP3K1,IP6K1,YES1,MAP2K7,NDUFB6,ND6,PDPK1,CCL2,NIN,IP6K2,NME2,ATP6V1B2,ATP5G2,SMG1,DUSP3,NTRK3, |
8.76E-4 |
GO:0042493
|
response to drug |
ALDH1A3,CCL5,ERBB2,ERBB3,NME2,MAT2A,CCL2,CDKN1A,TP53, |
1.08E-2 |
GO:0010033
|
response to organic substance |
NUP62,ERBB2,ERBB3,TFRC,RARA,PDPK1,LIN28B,CCL2,GLUL,CDKN1A,PANX1,LIN28A,MCL1,CCL5,NME2,MAT2A,EIF4EBP1, |
1.36E-2 |
GO:0008637
|
apoptotic mitochondrial changes |
MAP3K1,GGCT,BAK1,TP53, |
3.13E-2 |
GO:0006913
|
nucleocytoplasmic transport |
XPO1,NPM1,ATXN1,TNPO2,SMG1,NCKIPSD,TP53, |
3.79E-2 |
GO:0051169
|
nuclear transport |
XPO1,NPM1,ATXN1,TNPO2,SMG1,NCKIPSD,TP53, |
4.03E-2 |
GO:0042981
|
regulation of apoptosis |
ALDH1A3,NUP62,ERBB2,MAPK8,ERBB3,MAP3K1,NPM1,CCL2,CDKN1A,TP53,MCL1,G2E3,VEGFA,IP6K2,NME2,TNFAIP3,BAK1, |
4.07E-2 |
GO:0043067
|
regulation of programmed cell death |
ALDH1A3,NUP62,ERBB2,MAPK8,ERBB3,MAP3K1,NPM1,CCL2,CDKN1A,TP53,MCL1,G2E3,VEGFA,IP6K2,NME2,TNFAIP3,BAK1, |
4.48E-2 |
GO:0010941
|
regulation of cell death |
ALDH1A3,NUP62,ERBB2,MAPK8,ERBB3,MAP3K1,NPM1,CCL2,CDKN1A,TP53,MCL1,G2E3,VEGFA,IP6K2,NME2,TNFAIP3,BAK1, |
4.64E-2 |
GO:0050679
|
positive regulation of epithelial cell proliferation |
ERBB2,VEGFA,NME2,LAMB1, |
6.93E-2 |
GO:0048593
|
camera-type eye morphogenesis |
ALDH1A3,VEGFA,BAK1,SP1, |
8.43E-2 |
GO:0009725
|
response to hormone stimulus |
NUP62,CCL5,ERBB2,ERBB3,RARA,PDPK1,MAT2A,EIF4EBP1,CCL2,CDKN1A, |
8.52E-2 |
GO:0046854
|
phosphoinositide phosphorylation |
IP6K2,IP6K1,SMG1, |
8.73E-2 |
GO:0046777
|
protein amino acid autophosphorylation |
ERBB2,MAP3K1,YES1,SMG1,NTRK3, |
8.81E-2 |
GO:0046834
|
lipid phosphorylation |
IP6K2,IP6K1,SMG1, |
9.92E-2 |
|
|
|
|
|
|